Liver cancer drug combo study halted early

NCT ID NCT05220722

Terminated Disease control Sponsor: TriSalus Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to deliver an immune-boosting drug (SD-101) directly into the liver along with standard immunotherapy for people with advanced liver cancer. It included 23 adults whose cancer had not responded to prior treatment. The goal was to find a safe dose and see if the combination could shrink tumors. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma hepatocellular carcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA INTRAHEPATIC CHOLANGIOCARCINOMA

Contacts and locations

Show contact details

Locations

Columbia University

New York, New York, 10032, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
University of Colorado

Aurora, Colorado, 80045, United States